Inhibrx Biosciences, INC Form 4 insider transactions

Director Kristiina Vuori was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Director Jon Faiz Kayyem was granted 15,000 stock options in Inhibrx Biosciences, Inc. with an exercise price of $95.22.

Director Douglas Forsyth was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Director Kimberly Manhard was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Inhibrx Biosciences President David Matly was granted 50,000 stock options as part of a standard equity compensation package.

Viking Global Investors LP and affiliated entities reported the sale of 359,000 shares of Inhibrx Biosciences, Inc. common stock for $32.25 per share.

Inhibrx Biosciences, Inc. Director Kimberly Manhard was granted 15,000 stock options with an exercise price of $12.91, which will become fully exercisable on May 28, 2026.

Inhibrx Biosciences, Inc. Director Kristiina Vuori, MD, was granted 15,000 stock options with an exercise price of $12.91, which will become fully exercisable on May 28, 2026.

Inhibrx Biosciences, Inc. Director Jon Faiz Kayyem was granted 15,000 stock options with an exercise price of $12.91 per share, exercisable from May 28, 2026.

Inhibrx Biosciences, Inc. director Douglas Forsyth was granted 15,000 stock options with an exercise price of $12.91, aligning his interests with shareholder value.

Kelly Deck, CFO of Inhibrx Biosciences, acquired 15,000 stock options on April 1, 2025, according to a Form 4 filing with the SEC.

David Matly, President of Inhibrx Biosciences, acquired 50,000 stock options on April 1, 2025, according to a Form 4 filing.

Director Jon Faiz Kayyem reports a gift of 90,000 shares of Inhibrx Biosciences common stock and disclaims beneficial ownership of shares held in various trusts and custodial accounts.

Director Jon Faiz Kayyem transferred 500,000 shares of Inhibrx Biosciences stock to family trusts on December 16, 2024.

Director Jon Faiz Kayyem of Inhibrx Biosciences reported a gift of 52,000 common shares from a family trust to his adult children.

Director Jon Faiz Kayyem indirectly acquired shares of Inhibrx Biosciences through custodial accounts for his children.

Kristiina Vuori, a director of Inhibrx Biosciences, purchased 6,667 shares of common stock at $15 per share on October 3, 2024.

Inhibrx Biosciences CEO Mark Lappe has increased his indirect holdings in the company through purchases made by the Lappe Family Trust.

Kristiina Vuori, a director at Inhibrx Biosciences, recently purchased additional shares of the company's common stock, increasing her beneficial ownership.

Inhibrx Biosciences CEO Mark Lappe reports purchasing additional shares of the company's common stock through the Lappe Family Trust.

Inhibrx Biosciences CEO Mark Lappe has been actively purchasing company stock through personal and trust accounts, increasing his beneficial ownership.

Kristiina Vuori, a director of Inhibrx Biosciences, purchased 7,140 shares of common stock at $14 per share on August 29, 2024.

Director Kimberly Manhard purchased 10,000 shares of Inhibrx Biosciences (INBX) at an average price of $13.98 on August 28, 2024.

Director Douglas Forsyth has increased his indirect holdings in Inhibrx Biosciences through purchases made via the Forsyth Family Trust.

Inhibrx Biosciences CEO Mark Lappe recently purchased additional shares of the company's common stock through indirect holdings.

Director Jon Faiz Kayyem of Inhibrx Biosciences reports gifting shares of common stock to family members and trusts, with no monetary transaction involved.

Director Jon Faiz Kayyem reports purchasing additional shares of Inhibrx Biosciences, Inc. through a family trust.

Director Jon Faiz Kayyem reports multiple purchases of Inhibrx Biosciences (INBX) common stock, increasing his indirect holdings through a family trust.

Inhibrx, Inc. reports a distribution of Inhibrx Biosciences, Inc. common stock to its shareholders, resulting in changes in beneficial ownership.

Kristiina Vuori, a director at Inhibrx Biosciences, acquired stock options for 30,000 shares of common stock following the merger with a Sanofi subsidiary.